Clinical trials: Patients With Thyroid Cancer
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Medullary Thyroid Carcinoma
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo in subjects with locally advanced medullary thyroid cancer (MTC).
- Trial name
- SUMMIT (NCT01736878)
- Testing
- Sorafenib
- Where
- Germany
- Sponsor
- Eanm Research Ltd
Thyroid Neoplasms
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
- Trial name
- NCT00389441
- Testing
- AG-013736
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 52 people
- Sponsor
- Pfizer
Thyroid Cancer, RAI-Refractory Thyroid Cancer
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
The objective of this study is to demonstrate the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer including 1) Evaluation of extent (volume and pattern) of remnant tissue in post total…
- Trial name
- NCT06443866
- Testing
- Disease status detection, Theranostic dosimetry, I-124 PET/CT imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Miami Cancer Research Center, Inc.
Refractory Cancer
A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer
This is a single-center, open-label, single arm，exploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer.
- Trial name
- NCT03199677
- Testing
- Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Thyroid Nodules
Elastography Interest in the Management of Thyroid Nodules
Define an ultrasound/elastography benignity criteria in strategy management of a patient population carries one or more thyroid nodules.
- Trial name
- SWETHY (NCT01335828)
- Testing
- Medical ultrasound device (ShearWave system)
- Where
- France
- Volunteers
- 125 people
- Sponsor
- AdministrateurCIC
Thyroid Cancer
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.
- Trial name
- NCT04868045
- Testing
- Thyrotropin Releasing Hormone (TRH), levothyroxine, Hypothyroidism QOL questionnaire
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
This prospective, multi-centre, open label, non-randomised phase II trial aims restore radioiodine sensitivity in patients with NRAS or BRAFV600E mutant refractory thyroid cancer.
- Trial name
- I-FIRST (NCT05182931)
- Testing
- Dabrafenib 75 MG, Trametinib 2 MG
- Where
- 9 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Papillary Thyroid Cancer
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
The incidence of papillary thyroid cancer (PTC) has been on the rise in recent years, and 20%-50% of PTC patients will have lymph node metastasis.
- Trial name
- NCT06286631
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Thyroid Neoplasm, Lymphatic Metastasis
Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma
The purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (LNM) and to elucidate the factors that predict LNM in papillary thyroid carcinoma (PTC) with central neck metastasis (CNM) by…
- Trial name
- NCT01103557
- Testing
- prophylactic selective lateral neck dissection
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Pusan National University Hospital
DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
Subjects: patients with postoperative local recurrent or metastatic differentiated thyroid cancer . Experimental group: Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a…
- Conditions
- DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications
- Trial name
- NCT06405217
- Testing
- Recombinant Human Thyroid Stimulating Hormone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thyroid Cancer
A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
The study is to demonstrate non-inferior thyroid remnant first ablation success of Thyrogen and 131I compared to thyroid hormone withdrawal (THW) and 131I in patients with T4 tumour based on historical diagnostic whole body scan…
- Trial name
- NCT01736163
- Testing
- Thyrogen, 131I, Thyroid Hormone Withdrawal
- Where
- 9 sites in Germany, Italy and 2 more
- Volunteers
- 144 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumor, Lymphoma
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors.
- Trial name
- NCT00413075
- Testing
- oral belinostat
- Where
- 6 sites in United States, Denmark and 1 more
- Volunteers
- 121 people
- Sponsor
- Valerio Therapeutics
Diarrhea, Medullary Thyroid Cancer
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Diarrhea in patients with MTC (Medullary Thyroid Cancer) can be debilitating and, in some cases life threatening. Findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders.
- Trial name
- NCT01739634
- Testing
- CASAD
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Salient Pharmaceuticals Incorporated
Hyperthyroidism/Thyrotoxicosis, Hyperthyroidism; Goiter
Iodinated Contrast Media Induced Hyperthyroidism
The proper synthesis of thyroid hormones is dependent on adequate iodine supply. The mean daily iodine intake recommended by World Health Organization is 150 mg.
- Conditions
- Hyperthyroidism/Thyrotoxicosis, Hyperthyroidism; Goiter, Iodine Induced Thyrotoxicosis, Contrast Media Adverse Reaction
- Trial name
- NCT04304794
- Testing
- Administration of iodinated contrast media, Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
- Volunteers
- 36 people
- Sponsor
- Medical University of Warsaw
Advanced Solid Tumor
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1201 in subjects with advanced solid tumors.
- Trial name
- NCT05785728
- Testing
- DB-1202
- Where
- China
- Volunteers
- 150 people
- Sponsor
- DualityBio Inc.